Stockscreener 앱 받기
59.55
1.38%
-1.0003
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus
AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Canada
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - simplywall.st
AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - Yahoo Finance
AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com
AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today
AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat
H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada
Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com
AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq
HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus
H.C. Wainwright raises AnaptysBio stock price target to $66 - Investing.com UK
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus
Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates - Bitget
AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Mil - GuruFocus
AnaptysBio earnings beat by $0.71, revenue topped estimates - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
AnaptysBio Q4 Swings to Profit, Revenue Rises - marketscreener.com
AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan - TradingView
AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 71c - StreetInsider
Anaptysbio 10-K: $234.6M Revenue, $(0.46) EPS - TradingView
Planned AnaptysBio (NASDAQ: ANAB) split separates royalties from pipeline - Stock Titan
AnaptysBio, Inc. Announces Spin-off of Biopharma Operations to Form First Tracks Biotherapeutics, Targeting Q2 2026 - Quiver Quantitative
Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q4 Revenue $108.2M, vs. FactSet Est of $87.0M - marketscreener.com
AnaptysBio (NASDAQ: ANAB) Q4 profit, royalties surge and 2026 spin-off - Stock Titan
Commit To Buy AnaptysBio At $35, Earn 15.9% Annualized Using Options - Nasdaq
ANAB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ANAB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AnaptysBio, Inc. (ANAB) Stock Analysis: A Biotech With 21% Potential Upside - DirectorsTalk Interviews
FDA accepts Vanda’s imsidolimab application for rare skin disorder - Investing.com
FDA accepts Vanda’s imsidolimab application for rare skin disorder By Investing.com - Investing.com UK
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - ChartMill
AnaptysBio stock hits 52-week high at $57.73 By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $57.73 - Investing.com
Big Picture: Can AnaptysBio Inc grow without external fundingWeekly Trade Review & Proven Capital Preservation Tips - baoquankhu1.vn
How Anaptysbio Inc. (ANAB) Affects Rotational Strategy Timing - Stock Traders Daily
Skandinaviska Enskilda Banken AB publ Has $4.45 Million Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. (ANAB) Investor Outlook: Analyzing a 22.46% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
AnaptysBio (ANAB) to Release Quarterly Earnings on Thursday - Defense World
AnaptysBio, Inc. $ANAB Stock Holdings Trimmed by GSA Capital Partners LLP - MarketBeat
ANAB PE Ratio & Valuation, Is ANAB Overvalued - Intellectia AI
AnaptysBio (NASDAQ:ANAB) Insider Sells $540,000.00 in Stock - MarketBeat
AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking the 23.71% Potential Upside for Investors - DirectorsTalk Interviews
AnaptysBio Insider Sells $540,000 in Stock - National Today
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - MarketBeat
Page not foundAirwhon - MarketBeat
ANAB: Separation in Q2 will unlock value from Jemperli royalties and advance a promising clinical pipeline - TradingView
AnaptysBio stock hits 52-week high at $52.56 By Investing.com - Investing.com South Africa
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? - Yahoo Finance
(ANAB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Market Trends: Is AnaptysBio Inc a momentum stockDollar Strength & Real-Time Stock Price Movement Reports - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighShould You Buy? - MarketBeat
AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts - MarketBeat
0.50%
자본화:
|
볼륨(24시간):